Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 247

1.

Age is a critical determinant in recovery from multiple sclerosis relapses.

Conway BL, Zeydan B, Uygunoğlu U, Novotna M, Siva A, Pittock SJ, Atkinson EJ, Rodriguez M, Kantarci OH.

Mult Scler. 2018 Oct 10:1352458518800815. doi: 10.1177/1352458518800815. [Epub ahead of print]

PMID:
30303037
2.

Paraneoplastic neuronal intermediate filament autoimmunity.

Basal E, Zalewski N, Kryzer TJ, Hinson SR, Guo Y, Dubey D, Benarroch EE, Lucchinetti CF, Pittock SJ, Lennon VA, McKeon A.

Neurology. 2018 Oct 30;91(18):e1677-e1689. doi: 10.1212/WNL.0000000000006435. Epub 2018 Oct 3.

3.

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD.

Shosha E, Dubey D, Palace J, Nakashima I, Jacob A, Fujihara K, Takahashi T, Whittam D, Leite MI, Misu T, Yoshiki T, Messina S, Elsone L, Majed M, Flanagan E, Gadoth A, Huebert C, Sagen J, Greenberg BM, Levy M, Banerjee A, Weinshenker B, Pittock SJ.

Neurology. 2018 Oct 23;91(17):e1642-e1651. doi: 10.1212/WNL.0000000000006392. Epub 2018 Sep 26.

4.

Pain and the immune system: emerging concepts of IgG-mediated autoimmune pain and immunotherapies.

Xu M, Bennett DLH, Querol LA, Wu LJ, Irani SR, Watson JC, Pittock SJ, Klein CJ.

J Neurol Neurosurg Psychiatry. 2018 Sep 17. pii: jnnp-2018-318556. doi: 10.1136/jnnp-2018-318556. [Epub ahead of print]

PMID:
30224548
5.

Population-based study of "no evident disease activity" in MS.

Parks NE, Pittock SJ, Mandrekar J, Kantarci OH, Lucchinetti CF, Weinshenker BG, Keegan BM, Tobin WO, Tillema JM, Toledano M, Flanagan EP.

Neurol Neuroimmunol Neuroinflamm. 2018 Aug 16;5(6):e495. doi: 10.1212/NXI.0000000000000495. eCollection 2018 Nov.

6.

Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction.

Dubey D, Kothapalli N, McKeon A, Flanagan EP, Lennon VA, Klein CJ, Britton JW, So E, Boeve BF, Tillema JM, Sadjadi R, Pittock SJ.

J Neuroimmunol. 2018 Oct 15;323:62-72. doi: 10.1016/j.jneuroim.2018.07.009. Epub 2018 Jul 25.

PMID:
30196836
7.

Antiepileptic drug therapy in autoimmune epilepsy associated with antibodies targeting the leucine-rich glioma-inactivated protein 1.

Feyissa AM, Lamb C, Pittock SJ, Gadoth A, McKeon A, Klein CJ, Britton JW.

Epilepsia Open. 2018 Jun 25;3(3):348-356. doi: 10.1002/epi4.12226. eCollection 2018 Sep.

8.

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1.

Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN, Lepone LM, Zekeridou A, Pittock SJ, Hassan R, Schlom J, Gulley JL.

Ann Rheum Dis. 2018 Sep 5. pii: annrheumdis-2018-213777. doi: 10.1136/annrheumdis-2018-213777. [Epub ahead of print] No abstract available.

PMID:
30185415
9.

Posttransplant autoimmune encephalitis.

Cohen DA, Lopez-Chiriboga AS, Pittock SJ, Gadoth A, Zekeridou A, Boilson BA, Hogan WJ, Poterucha JJ, Wilton KM, Lin Y, Flanagan EP.

Neurol Neuroimmunol Neuroinflamm. 2018 Aug 20;5(6):e497. doi: 10.1212/NXI.0000000000000497. eCollection 2018 Nov. No abstract available.

10.

LGI1 and CASPR2 neurological autoimmunity in children.

López-Chiriboga AS, Klein C, Zekeridou A, McKeon A, Dubey D, Flanagan EP, Lennon VA, Tillema JM, Wirrell EC, Patterson MC, Gadoth A, Aaen JG, Brenton JN, Bui JD, Moen A, Otten C, Piquet A, Pittock SJ.

Ann Neurol. 2018 Sep;84(3):473-480. doi: 10.1002/ana.25310.

PMID:
30076629
11.

Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.

Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer JP, Leavitt JA, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Tobin WO, Keegan BM, Lucchinetti CF, Kantarci OH, McClelland CM, Lee MS, Bennett JL, Pelak VS, Chen Y, VanStavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Brazis PW, Sagen J, Pittock SJ.

Am J Ophthalmol. 2018 Nov;195:8-15. doi: 10.1016/j.ajo.2018.07.020. Epub 2018 Jul 26.

PMID:
30055153
12.

Spontaneous posterior spinal artery infarction: An under-recognized cause of acute myelopathy.

Zalewski NL, Rabinstein AA, Wijdicks EFM, Petty GW, Pittock SJ, Mantyh WG, Flanagan EP.

Neurology. 2018 Aug 28;91(9):414-417. doi: 10.1212/WNL.0000000000006084. Epub 2018 Jul 25. No abstract available.

PMID:
30045962
13.

Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis.

Sechi E, Morris PP, McKeon A, Pittock SJ, Hinson SR, Weinshenker BG, Aksamit AJ, Krecke KN, Kaufmann TJ, Jolliffe EA, Zalewski NL, Zekeridou A, Wingerchuk DM, Jitprapaikulsan J, Flanagan EP.

J Neurol Neurosurg Psychiatry. 2018 Jul 21. pii: jnnp-2018-318004. doi: 10.1136/jnnp-2018-318004. [Epub ahead of print] No abstract available.

PMID:
30032117
14.

Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders.

López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, Jitprapaikulsan J, Kothapalli N, Tillema JM, Chen J, Weinshenker B, Wingerchuk D, Sagen J, Gadoth A, Lennon VA, Keegan BM, Lucchinetti C, Pittock SJ.

JAMA Neurol. 2018 Nov 1;75(11):1355-1363. doi: 10.1001/jamaneurol.2018.1814.

PMID:
30014148
15.

Autoimmune septin-5 cerebellar ataxia.

Honorat JA, Lopez-Chiriboga AS, Kryzer TJ, Fryer JP, Devine M, Flores A, Lennon VA, Pittock SJ, McKeon A.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 9;5(5):e474. doi: 10.1212/NXI.0000000000000474. eCollection 2018 Sep.

16.

Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1 year.

Dubey D, Hinson SR, Jolliffe EA, Zekeridou A, Flanagan EP, Pittock SJ, Basal E, Drubach DA, Lachance DH, Lennon VA, McKeon A.

J Neuroimmunol. 2018 Aug 15;321:157-163. doi: 10.1016/j.jneuroim.2018.04.016. Epub 2018 Apr 27.

PMID:
29793728
17.

Elevated LGI1-IgG CSF index predicts worse neurological outcome.

Gadoth A, Zekeridou A, Klein CJ, Thoreson CJ, Majed M, Dubey D, Flanagan EP, McKeon A, Jenkins SM, Lennon VA, Pittock SJ.

Ann Clin Transl Neurol. 2018 Apr 2;5(5):646-650. doi: 10.1002/acn3.561. eCollection 2018 May.

18.

Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.

Jitprapaikulsan J, Chen JJ, Flanagan EP, Tobin WO, Fryer JP, Weinshenker BG, McKeon A, Lennon VA, Leavitt JA, Tillema JM, Lucchinetti C, Keegan BM, Kantarci O, Khanna C, Jenkins SM, Spears GM, Sagan J, Pittock SJ.

Ophthalmology. 2018 Oct;125(10):1628-1637. doi: 10.1016/j.ophtha.2018.03.041. Epub 2018 Apr 30.

PMID:
29716788
19.

Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis.

Jitprapaikulsan J, Lopez Chiriboga AS, Flanagan EP, Fryer JP, McKeon A, Weinshenker BG, Pittock SJ.

JAMA Neurol. 2018 Jul 1;75(7):892-895. doi: 10.1001/jamaneurol.2018.0805. No abstract available.

PMID:
29710213
20.

Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies.

Guerra H, Pittock SJ, Moder KG, Fryer JP, Gadoth A, Flanagan EP.

Mayo Clin Proc. 2018 Sep;93(9):1299-1304. doi: 10.1016/j.mayocp.2018.02.006. Epub 2018 Apr 11.

PMID:
29655487
21.

Reply to "epidemiology of autoimmune versus infectious encephalitis".

Dubey D, Pittock SJ, Toledano M, Flanagan EP.

Ann Neurol. 2018 May;83(5):1038. doi: 10.1002/ana.25230. No abstract available.

PMID:
29637594
22.

GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies.

Liimatainen S, Honnorat J, Pittock SJ, McKeon A, Manto M, Radtke JR; T1D Exchange Biobank, Hampe CS.

Orphanet J Rare Dis. 2018 Apr 10;13(1):55. doi: 10.1186/s13023-018-0787-5.

23.

Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.

Chen JJ, Tobin WO, Majed M, Jitprapaikulsan J, Fryer JP, Leavitt JA, Flanagan EP, McKeon A, Pittock SJ.

JAMA Ophthalmol. 2018 Apr 1;136(4):419-422. doi: 10.1001/jamaophthalmol.2017.6757.

PMID:
29470571
24.

Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders.

Hinson SR, Lopez-Chiriboga AS, Bower JH, Matsumoto JY, Hassan A, Basal E, Lennon VA, Pittock SJ, McKeon A.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 23;5(2):e438. doi: 10.1212/NXI.0000000000000438. eCollection 2018 Mar.

25.

CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes.

Gurtner KM, Shosha E, Bryant SC, Andreguetto BD, Murray DL, Pittock SJ, Willrich MAV.

Clin Chem Lab Med. 2018 Jun 27;56(7):1071-1080. doi: 10.1515/cclm-2017-0901.

PMID:
29455184
26.

ITPR1 autoimmunity: Frequency, neurologic phenotype, and cancer association.

Alfugham N, Gadoth A, Lennon VA, Komorowski L, Scharf M, Hinson S, McKeon A, Pittock SJ.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 8;5(1):e418. doi: 10.1212/NXI.0000000000000418. eCollection 2018 Jan. No abstract available.

27.

MRI findings in glutamic acid decarboxylase associated autoimmune epilepsy.

Fredriksen JR, Carr CM, Koeller KK, Verdoorn JT, Gadoth A, Pittock SJ, Kotsenas AL.

Neuroradiology. 2018 Mar;60(3):239-245. doi: 10.1007/s00234-018-1976-6. Epub 2018 Jan 20.

PMID:
29353399
28.

Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis.

Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, Gadoth A, Smith CY, Bryant SC, Klein CJ, Aksamit AJ, Toledano M, Boeve BF, Tillema JM, Flanagan EP.

Ann Neurol. 2018 Jan;83(1):166-177. doi: 10.1002/ana.25131.

PMID:
29293273
29.

Calcium channel autoimmunity: Cerebellar ataxia and lambert-eaton syndrome coexisting.

Zalewski N, Lennon VA, Pittock SJ, Mckeon A.

Muscle Nerve. 2017 Dec 22. doi: 10.1002/mus.26053. [Epub ahead of print]

PMID:
29272039
30.

Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM.

Martinez-Thompson JM, Snyder MR, Ettore M, McKeon A, Pittock SJ, Roforth MM, Mandrekar J, Mauermann ML, Taylor BV, Dyck PJB, Windebank AJ, Klein CJ.

Muscle Nerve. 2018 Jun;57(6):1000-1005. doi: 10.1002/mus.26051. Epub 2018 Jan 26.

PMID:
29272035
31.

Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases.

Dubey D, Lennon VA, Gadoth A, Pittock SJ, Flanagan EP, Schmeling JE, McKeon A, Klein CJ.

Neurology. 2018 Jan 9;90(2):e103-e110. doi: 10.1212/WNL.0000000000004803. Epub 2017 Dec 8.

PMID:
29222126
32.

Optic Disc Edema in Glial Fibrillary Acidic Protein Autoantibody-Positive Meningoencephalitis.

Chen JJ, Aksamit AJ, McKeon A, Pittock SJ, Weinshenker BG, Leavitt JA, Morris PP, Flanagan EP.

J Neuroophthalmol. 2018 Sep;38(3):276-281. doi: 10.1097/WNO.0000000000000593.

PMID:
29210929
33.

Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management.

Shosha E, Pittock SJ, Flanagan E, Weinshenker BG.

Mult Scler. 2017 Dec;23(14):1808-1817. doi: 10.1177/1352458517740215. Review.

PMID:
29154728
34.

Purkinje cell cytoplasmic antibody type I (anti-Yo): predictive of gastrointestinal adenocarcinomas in men.

Linnoila J, Guo Y, Gadoth A, Raghunathan A, Parks B, McKeon A, Lucchinetti CF, Lennon VA, Pittock SJ.

J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1116-1117. doi: 10.1136/jnnp-2017-316829. Epub 2017 Nov 15. No abstract available.

PMID:
29142142
35.

Breast cancer-related paraneoplastic neurologic disease.

Murphy BL, Zalewski NL, Degnim AC, McKeon A, Flanagan EP, Pittock SJ, Habermann EB.

Breast Cancer Res Treat. 2018 Feb;167(3):771-778. doi: 10.1007/s10549-017-4566-0. Epub 2017 Nov 7.

PMID:
29116466
36.

B-cell-targeted therapies in relapsing forms of MS.

Dubey D, Forsthuber T, Flanagan EP, Pittock SJ, Stüve O.

Neurol Neuroimmunol Neuroinflamm. 2017 Oct 23;4(6):e405. doi: 10.1212/NXI.0000000000000405. eCollection 2017 Nov. Review.

37.

LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes.

Binks SNM, Klein CJ, Waters P, Pittock SJ, Irani SR.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):526-534. doi: 10.1136/jnnp-2017-315720. Epub 2017 Oct 21. Review.

38.

Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS).

Tobin WO, Guo Y, Krecke KN, Parisi JE, Lucchinetti CF, Pittock SJ, Mandrekar J, Dubey D, Debruyne J, Keegan BM.

Brain. 2017 Sep 1;140(9):2415-2425. doi: 10.1093/brain/awx200.

PMID:
29050399
39.

PRES leading to the diagnosis of McArdle disease.

Martinez-Thompson JM, Pittock SJ, Milone M.

J Clin Neurosci. 2017 Dec;46:62-64. doi: 10.1016/j.jocn.2017.08.013. Epub 2017 Sep 5.

PMID:
28887083
40.

IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients.

Honorat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK, Hinson SR, Lederer S, Kumar N, Gadoth A, Lennon VA, Pittock SJ, McKeon A.

Neurol Neuroimmunol Neuroinflamm. 2017 Jul 18;4(5):e385. doi: 10.1212/NXI.0000000000000385. eCollection 2017 Sep.

41.

Dacrystic seizures-a cry for help.

Gadoth A, Singh J, Britton JW, Flanagan EP, Pittock SJ.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e372. doi: 10.1212/NXI.0000000000000372. eCollection 2017 Jul. No abstract available.

42.

Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients.

Gadoth A, Pittock SJ, Dubey D, McKeon A, Britton JW, Schmeling JE, Smith A, Kotsenas AL, Watson RE, Lachance DH, Flanagan EP, Lennon VA, Klein CJ.

Ann Neurol. 2017 Jul;82(1):79-92. doi: 10.1002/ana.24979.

PMID:
28628235
43.

Autoimmune Neurology of the Central Nervous System.

Tobin WO, Pittock SJ.

Continuum (Minneap Minn). 2017 Jun;23(3, Neurology of Systemic Disease):627-653. doi: 10.1212/CON.0000000000000487. Review.

PMID:
28570322
44.

Predictive models in the diagnosis and treatment of autoimmune epilepsy.

Dubey D, Singh J, Britton JW, Pittock SJ, Flanagan EP, Lennon VA, Tillema JM, Wirrell E, Shin C, So E, Cascino GD, Wingerchuk DM, Hoerth MT, Shih JJ, Nickels KC, McKeon A.

Epilepsia. 2017 Jul;58(7):1181-1189. doi: 10.1111/epi.13797. Epub 2017 May 26.

45.

Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder.

Asgari N, Flanagan EP, Fujihara K, Kim HJ, Skejoe HP, Wuerfel J, Kuroda H, Kim SH, Maillart E, Marignier R, Pittock SJ, Paul F, Weinshenker BG.

Neurol Neuroimmunol Neuroinflamm. 2017 Apr 21;4(4):e343. doi: 10.1212/NXI.0000000000000343. eCollection 2017 Jul.

46.

Diagnosis and management of spinal cord emergencies.

Flanagan EP, Pittock SJ.

Handb Clin Neurol. 2017;140:319-335. doi: 10.1016/B978-0-444-63600-3.00017-9. Review.

PMID:
28187806
47.

Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica.

Guo Y, Weigand SD, Popescu BF, Lennon VA, Parisi JE, Pittock SJ, Parks NE, Clardy SL, Howe CL, Lucchinetti CF.

Acta Neuropathol. 2017 Apr;133(4):597-612. doi: 10.1007/s00401-017-1682-1. Epub 2017 Feb 9.

48.

Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients.

Flanagan EP, Hinson SR, Lennon VA, Fang B, Aksamit AJ, Morris PP, Basal E, Honorat JA, Alfugham NB, Linnoila JJ, Weinshenker BG, Pittock SJ, McKeon A.

Ann Neurol. 2017 Feb;81(2):298-309. doi: 10.1002/ana.24881.

PMID:
28120349
49.

Association of Extension of Cervical Cord Lesion and Area Postrema Syndrome With Neuromyelitis Optica Spectrum Disorder.

Dubey D, Pittock SJ, Krecke KN, Flanagan EP.

JAMA Neurol. 2017 Mar 1;74(3):359-361. doi: 10.1001/jamaneurol.2016.5441. No abstract available.

PMID:
28097302
50.

Microtubule-associated protein 1B: Novel paraneoplastic biomarker.

Gadoth A, Kryzer TJ, Fryer J, McKeon A, Lennon VA, Pittock SJ.

Ann Neurol. 2017 Feb;81(2):266-277. doi: 10.1002/ana.24872.

PMID:
28074593

Supplemental Content

Loading ...
Support Center